Skip to main content
. 2022 Aug 1;11(15):2367. doi: 10.3390/cells11152367

Figure 1.

Figure 1

Decreased expression of CD90, CD73, and CD105 on Pre-T2D IPFP-ASCs. (A) Flow cytometry for CD90 and CD105 demonstrated decreased expression in Pre-T2D IPFP-ASCs compared to those from Non-T2D and T2D groups (n = 3, * p < 0.05). (B) CFU assay illustrated increased self-renewal properties in T2D IPFP-ASCs compared to Non-T2D (n = 3, * p < 0.05). (C–F) RT-qPCR for common adipokines in ASCs and adipocyte differentiated ASCs demonstrated no significant difference in adipogenic potential between Non-T2D, Pre-T2D, and T2D IPFP-ASCs (n = 3, * p < 0.05, *** p < 0.001, **** p < 0.0001). Non-T2D IPFP ASCs 7-Day is the control Group set as 1. Non-T2D: IPFP-ASCs from donors without Type II diabetes mellitus, Pre-T2D: IPFP-ASCs from donors with pre-Type II diabetes mellitus, T2D: IPFP-ASCs from donors with type II diabetes mellitus, 7D: Confluent ASCs, AQ: Adipocyte Differentiated ASCs.